Dispatches from CPhI
Gene therapy to drive viral and biologics market, says SAFC
This content item was originally published on www.biopharma-reporter.com, a William Reed online publication.
The expansion includes two manufacturing suites that feature disposable bioreactor technologies to support the development and production of viral vaccines and viral therapeutics.
SAFC Pharma business development and marketing director David Backer spoke with in-PharmaTechnologist at CPhI in Madrid, Spain, explaining that the firm expects gene therapy to be the key driver for this type of contract manufacturing offering.
Validation work at the facility is under and SAFC Pharma expects to begin manufacturing operations by the end of the year.
